M249 melanoma cells: Vemurafenib and Selumetinib resistant through BRAF double minutes vs. parental
收藏NIAID Data Ecosystem2026-03-13 收录
下载链接：
https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE153526
下载链接
链接失效反馈官方服务：
资源简介：
CGH profiling of M249 melanoma cell line treated with step-wise increasing Vemurafenib and Selumetinib to develop resistance (VSR). The resistance mechanims was through BRAF amplification in double minute (DM) format. The control cell line is untreated M249. Two-condition experiment, M249 Parental vs M249 VSR DM. Biological replicates: 1 control replicate, 1 treated replicate.
创建时间：
2022-03-21
